We hypothesize that a lower adiposity at start of GH therapy in SGA children and especially in adolescents might induce a lesser degree of adrenal hyperandrogenism and/or compensatory hyperinsulinemia causing less bone age acceleration [17, 18]. The gene discussed is GH1; the disease is hyperinsulinism.